Multiple Myeloma Survival With Stem Cell Transplant

All things considered while the autologous transplant can make the myeloma go away for a period of time even years it does not cure the growth and inevitably the myeloma back.

Multiple myeloma survival with stem cell transplant.

In allogeneic transplantation stem cells are given by a donor most commonly a brother or sister. A stem cell transplant replaces unhealthy blood cells with healthy ones. People who have autologous or allogeneic transplants first receive high dose chemotherapy to kill the cancer cells. The long term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997 through with the introduction of new medicines a large review study reports.

We here analyze factors influencing survival in 865 newly diagnosed mm patien. A population based study published correction appears in blood. The standard of care for fit multiple myeloma patients is to receive high dose chemotherapy hdt with autologous stem cell rescue otherwise known as autologous stem cell transplant asct after completion of induction therapy. Stem cell transplant for multiple myeloma.

Autologous stem cell transplantation is more common for multiple myeloma but either type of transplant can be used. It can be a strong weapon in your fight against multiple myeloma. Older patients and those with low risk disease show the greatest gains over time while people with high risk factors showed the least change its researchers said. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma.

In a stem cell transplant the patient gets high dose chemotherapy to kill the cells in the bone marrow. It isn t a cure but compared to chemotherapy alone a. When stem cell transplants were first developed the new stem cells came from bone marrow and so this was known as a bone marrow. The widespread use of high dose therapy and autologous stem cell transplantation asct as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma mm enabling long term survival.

Then the patient receives new healthy blood forming stem cells.